Skip to main content

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Projects

Neurologia Pediàtrica (GRC)

IP: Alfons Macaya Ruíz
Collaborators: Susana Boronat Guerero, Francina Munell Casadesus, Neurologia Pediàtrica (GRC), Anna Marcé Grau, Miquel Raspall Chaure, Mireia Del Toro Riera, Marta Vila Pueyo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 1087
Duration: 01/01/2014 - 31/12/2016

The working hypothesis of this grant is that NMJ dysfunction is contributing to SMA. Therefore we propose to understand the dysfunction of NMJ in SMA and find specific molecules that can restore the NMJ functionality and improve the quality of the life o

IP: Francina Munell Casadesus
Collaborators: The working hypothesis of this grant is that NMJ dysfunction is contributing to SMA. Therefore we propose to understand the dysf
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 91022.4
Reference: 2013 BP_B 00083
Duration: 01/10/2014 - 30/09/2016

Potencial terapéutico de los estrógenos en la enfermedad de Duchenne: efectos y mecanismos de acción sobre las células satélite y macrófagos

IP: Francina Munell Casadesus
Collaborators: Maria Jose Pérez García, Mireia Del Toro Riera, Elena Antima Martinez Saez
Funding agency: Instituto de Salud Carlos III
Funding: 57475
Reference: PI13/00052
Duration: 01/01/2014 - 30/09/2017

Neurociències

IP: Francina Munell Casadesus
Collaborators: Neurociències
Funding agency: Instituto de Salud Carlos III
Funding: 99000
Reference: CA12/00492
Duration: 31/01/2013 - 30/01/2016

Related news

The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Related professionals

Maria Josefa Azpiroz Franch

Maria Josefa Azpiroz Franch

Predoctoral researcher
Cardiovascular Diseases
Read more
Elena Vargas Accarino

Elena Vargas Accarino

Postdoctoral researcher
Liver Diseases
Read more
Natalia Avani Da Silva

Natalia Avani Da Silva

Gestió i Administració
Communication Unit
Communication Directorate
Read more
Piero Arturo Alberti Delgado

Piero Arturo Alberti Delgado

Predoctoral researcher
General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.